Fulgent Genetics Q4 revenue $251.7M, full year 2021 revenue $992.6M, core revenue up 236% YoY

Fulgent Genetics, Inc.

Q4 revenue $251.7M; full year 2021 revenue $992.6M, up 135% year-over-year.
Core revenue (ex-COVID) rose 234% YoY to $40.1M in Q4; full year core rev $122.6M (+236%).
GAAP net income $104.3M ($3.34 EPS) in Q4; full year GAAP net income $507.4M ($16.38 EPS).
Non-GAAP income $108.7M ($3.48 EPS) in Q4; adjusted EBITDA $159.8M.
Cash, cash equivalents & marketable securities $935.5M as of Dec 31, 2021; cash from ops $77.1M in Q4.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.